RATIONALE: Topical mast cell stabilizers are used for allergic conjunctivitis, but their efficacy as compared to topical corticosteroids is not known. We studied the non-inferiority of topical NaabakÒ versus FluconÒ during controlled exposures to airborne Bet v1 in Strasbourg EEC. METHODS: 24 adult subjects with moderate allergic conjunctivitis to birch pollen were included in a randomized, single-blind, cross-over study. All patients had a positive Conjunctival Provocation Test (CPT). Subjects were allocated to one of the 2 treatment sequences during 5 days before exposures. Conjunctival response was assessed by Abelson score (positive if > _5) using a slit-lamp every 10 minutes during 4 hours of 40 ng/m 3 of Bet v1 in 2 consecutive days. RESULTS: After treatment, the mean quantity of Bet v 1 was not significantly different between NaabakÒ and FluconÒ group (1.32 ng, versus 1.30 ng). Time necessary to obtain a conjunctival response was statistically different with FluconÒ and NaabakÒ compared to baseline. A priming effect of exposure was found between exposure 1 and 2 (increase risk developing a positive conjunctival by 2.3 on the second day). CONCLUSIONS: For the first time, the non-inferiority of NaabakÒ versus FluconÒ regarding the quantity of allergen responsible of a conjunctival response has been confirmed. The efficacy of the 2 treatments was demonstrated. A priming effect on conjunctival response was shown. The EEC appears to be a good model to assess the efficacy of topical treatments in allergic conjunctivitis. Federal Unviersity od São Paulo, São Paulo, Brazil. RATIONALE: Vernal keratoconjunctivitis (VKC) is considered a severe form of conjunctival allergic disease. The quality of life is severely impaired and treatment is complex and poorly responsive. The objective of this study was to evaluate the ophthalmologic clinical improvement with the use of omalizumab (OM). METHODS: Evaluation of three patients in the use of OM with objective score (OS -up to 8) and subjective (SS -up to 10) score (Spadavecchia et al., 2006) for clinical evaluation on days 0 and 180 and also the evaluation of the allergen sensitization performed through ImmunoCAP ISACÒ. RESULTS: Patient 1, male, 6 years; patient 2, female, 23 years; patient 3, male, 15 years. All with allergic rhinitis, severe asthma and VKC refractory to classic therapies, including oral immunosuppression and immunotherapy. All patients presented significant sensitivity to mites (nDer p1 and rBlo t5). The OM was indicated for asthma in regular doses. Regarding the scores: the initial values were SO 7 and SS 9,5; SO 7.5 and SS 8; SO 8 and SS 10. After 180 days of treatment with OM, the values were 4/5; 3/5; 4,5 / 4 respectively. Significant decrease in asthma symptoms and allergic rhinitis was also observed. CONCLUSIONS: OM is a humanized monoclonal antibody that binds circulating free IgE, thereby controlling the inflammatory process. In the reported cases, improvement in ocular symptoms was evident, but further studies are needed to prove the efficacy and safety of OM in VKC.
